Fosun Pharmaceutical

Pharma shares like Aurobindo Pharma, Zydus Lifesciences, Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals may rise up to 14 per cent.

Barring Sun Pharmaceutical Industries, which is anticipated to rally up to 10 per cent; other stocks indicate weak bias, as per technical charts

With the acquisition, Gland pharma may also get access to global companies like AstraZeneca, Sanofi, Mylan, and Organon

After the anti-diabetic market, India's cardiac market in for a shake-up

Fosun Pharma, a listed arm of Chinese conglomerate Fosun International Ltd., has been working with an adviser as it informally gauges interest in its controlling stake in Gland, the people said

Fosun Pharma, a listed arm of Chinese conglomerate Fosun International Ltd., has been working with an adviser as it informally gauges interest in its controlling stake in Gland

In a Q&A, the firm's US business head and its group CFO talk about their plans to scale the specialty products business further, and dwell on the company's strategies post-pandemic

The share of specialty medicines in overall pharmaceutical spending has been consistently increasing over the past decade, from 22 per cent in 2011 to 39 per cent in 2021

Gross sales up 10.1% YoY to Rs 10,644 cr; EBITDA at Rs 2,884.4 cr, with a margin of 26.8%

Stocks to watch today: HDFC, Sun Pharma, and Cipla will report their June quarter results on Friday, July 29; Dr Reddy's saw 108 per cent YoY rise in consolidated net profit to Rs 1,187.6 crore in Q1.

'Cipla has so many capabilities that for anything we need to do, we say we can do it'

Having consolidated its presence across geographies, the pharma major is looking at acquisitions

Germany, which was earlier India's top European export destination (eighth position), has now dropped two ranks to 10th place

Outlook for Indian drug exporters turned positive on prospects of firm exports amid the ongoing geo-political scenario, said analysts

Sun Pharma announced that its subsidiary Taro Pharmaceuticals USA Inc has completed the acquisition of subsidiary companies of Galderma

Anti-covid drug approval, new facility are the near term triggers for the pharma firm's stock

The diabetes segment has been growing faster than the country's overall drug market

Fosun Pharma and Fosun International said following the completion of the acquisition, Gland Pharma has become an indirect non-wholly owned subsidiary of Fosun Pharma and Fosun International

India allows foreign investment of up to 100% in pharmaceutical sector but above 74% requires govt approval

Agrees to cut size of stake in Hyderabad-based injectable maker to 74%, after earlier proposal to acquire 86% met approval roadblock